Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review Abstract #2941

Introduction: Neuroendocrine tumors (NETs) comprise <1% of all bladder tumors,characterized by poor prognosis. These tumors may be either pure or impure, intermixed with urothelial carcinoma. There is currently no therapeutic consensus. We report the case of primary impure neuroendocrine carcinoma (NEC).
Aim(s): The present case highlights the importance of immunohistochemistry in arriving at an accurate diagnosis, and discuss therapeutic options and prognosis.
Materials and methods: A 66-year-old male patient presented to hospital with hematuria.US showed a suspicious mass in the urinary bladder.CT revealed lobulated mass along the left lateral wall of the bladder.Cystoscopy revealed a large broad-based tumor in the bladder.A transurethral resection of the tumor was performed.Histopathological examination revealed a tumor composed of 2 different components.The major component corresponded to urothelial carcinoma.The other tumor component was composed of small cell NEC.Immunohistochemical analysis revealed a positive staining result for synaptophysin,CD 56,and a negative staining result for Chromogranin.Ki67 was about 30%.A complete gastrointestinal endoscopic evaluation and CT were normal.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Mohammed Alaeddine Saidi
Authors: Saidi M A, Ghomari S

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1176 Clinical and Pathologic Characteristics of Small Cell Neuroendocrine Carcinoma of the Bladder
Introduction: Small cell carcinoma of the bladder (SCC) is a poorly differentiated neuroendocrine (NE) neoplasm accounting less than 1% of all bladder tumors, 1/3 are admixed with conventional urothelial carcinoma and hematuria is the most common clinical presentation. The unknown etiology and natural history of SCC represent a challenge for its diagnosis and treatment.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Luis Perez-Casanova
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2690 Marked Response to Nab-Paclitaxel in Advanced Neuroendocrine Carcinoma of Nasal Sinuses: A Case Report
Introduction: Sinonasal neuroendocrine carcinomas (SNECs) are a very rare and high-grade malignant epithelial neoplasm that is usually associated with a poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Zhirong Qi
Authors: Qi Z, Zhang Y, Li Y, Wang C, ...
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova
#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...